A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01829035|
Recruitment Status : Completed
First Posted : April 11, 2013
Last Update Posted : March 29, 2018
This is a randomized, multi-center, open-labeled, phase III study in patients with advanced HCC. A total of 338 patients will be randomized (1:1) into one of the two treatment arms, to receive sorafenib with (Arm Combination-treatment; Arm C) or without (Arm Sorafenib alone treatment; Arm S) cTACE.
All the patients will be initially given sorafenib within 72 hours after the randomization. Treatment should continue until the criteria for treatment discontinuation are met.
After the treatment period, patients will undergo follow up for survival every 12 weeks (±7 days) from the last dose, and the survival follow up will be performed for at least 1.5 years after the last patient's last treatment.
|Condition or disease||Intervention/treatment||Phase|
|Advanced Adult Hepatocellular Carcinoma||Other: Conventional Transarterial Chemoembolization (cTACE)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||339 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)|
|Actual Study Start Date :||February 21, 2013|
|Actual Primary Completion Date :||June 21, 2017|
|Actual Study Completion Date :||June 21, 2017|
No Intervention: Arm S
sorafenib 400mg bid daily po until progression
Experimental: Arm C
after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
Other: Conventional Transarterial Chemoembolization (cTACE)
Concurrent use of the following material/drug is defined as cTACE in this trial.
- The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects [ Time Frame: 3.5 years ]
- Time to progression (TTP)in patients [ Time Frame: 3.5 years ]
- Tumor response rate (TRR)in patients [ Time Frame: 3.5 years ]
- Progression free survival(PFS)will be evaluated [ Time Frame: 3.5 years ]
- Evaluation of adverse events [ Time Frame: 3.5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829035
|Korea, Republic of|
|National Cancer Center, Korea|
|Seoul, Korea, Republic of|
|Principal Investigator:||Joong-Won Parkr, Ph.D.||National Cancer Center, Korea|